Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb541 and XmAb808 in Advanced Solid Tumors
NCT07593092Phase 1Recruiting
- Sponsor
- Xencor
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XmAb541 and xmab808 in ovarian cancer, sponsored by Xencor. Primary endpoints: Incidence of Adverse Events and Incidence of dose-limiting toxicities. Started Jun 2026; status: recruiting.
02
Drugs
XmAb541xmab808
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07593092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593092.